Mark Anderson
We are witnessing an incredible time for the biotech industry in Oxford, UK. A new generation of startups is emerging, using cutting-edge technologies to improve human health and tackle some of the world’s biggest challenges. These startups, all of which were launched in 2020 or later, are at the forefront of groundbreaking discoveries and solutions in the field of biotechnology. This article will highlight some of these innovative startups and give a brief overview of their groundbreaking work.
Oxford has long been a breeding ground for innovation, particularly in the fields of science and technology. Its rich history as a leading educational and research hub has paved the way for an exciting new generation of biotech startups. These companies are not only developing innovative solutions to medical and environmental problems but are also contributing significantly to Oxford’s thriving startup ecosystem.
The biotech industry is a rapidly evolving field, and Oxford-based startups are playing a crucial role in this evolution. From harnessing the power of machine learning to addressing sustainability in agriculture, these companies are changing the landscape of biotechnology. Let’s take a closer look at some of Oxford’s most exciting biotech startups.
Kyomei
Founded in 2021, Kyomei is developing a meat protein production system using the principles of plant cell biology. The company aims to produce flavourful meat alternatives, thus addressing the increasing demand for sustainable food solutions.
coding.bio
Operating in the intersection of Biotechnology, Artificial Intelligence, and Therapeutics, coding.bio is a promising startup co-founded by Simon Bornschein. Detailed information about their work is not readily available, but their industry placement indicates exciting possibilities.
Etcembly
Located in Hanwell, Oxfordshire, Etcembly leverages machine learning to develop immunotherapies. They aim to create the world’s largest machine learning database and utilise their immunology expertise to engineer powerful and safe TCR immunotherapies.
Oxford Silk Phage Technologies
Co-founded by James Gilbert and Stephanie Lesage, Oxford Silk Phage Technologies is tackling the problem of surgical implant and wound infections. They create antibacterial biomaterial technology combining silk with bacteriophages to prevent infections before they start.
MetaGuideX
MetaGuideX operates in the fields of Biotechnology, Health Care, Health Diagnostics, and Life Science. The specifics of their work are not well documented, but their placement in various medical disciplines foretells pioneering developments.
HydRegen
Founded in 2020 and based in Oxford, HydRegen supplies sustainable solutions for chemical manufacturing, aligning Biopharma and Biotechnology with sustainable solutions.
Nanolyse Technologies
Nanolyse Technologies offers groundbreaking innovations in analytical science. Founded by Dr Imad Ahmed in 2020, they are developing simple, low-cost chemical testing and measuring instruments to meet global needs across industries such as environment, food, biomedical, mining, and nuclear.
T-Cypher Bio
Co-founded by Graham Ogg, T-Cypher Bio is an early-stage biotech company. Their D-Cypher integrated platform aims to transform the treatment of solid tumors as well as autoimmune, inflammatory, and infectious diseases with its TCR-based therapeutics.
Accession Therapeutics
Accession Therapeutics, co-founded by Bent Jakobsen, Francis Yuan, and Nick Cross, is developing its Trocept platform to treat some of the most intractable and widespread forms of cancer. Its technology incorporates cancer-tropic viruses, revolutionising cancer cell targeting and eliminating systemic toxicity.
Alethiomics
Co-founded by Adam Mead and Bethan Psaila, Alethiomics is a pre-clinical biotech company. They use single-cell multi-omic technology to discover and develop life-changing treatments for patients with blood cancer.
OxVax
Founded by Marcelo Bravo, OxVax is focusing on the development of an advanced next-generation dendritic cell vaccine platform to treat solid tumour cancers.
